Literature DB >> 22768894

In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment.

Stefan Pscherer1, Martin Larbig, Berndt von Stritsky, Andreas Pfützner, Thomas Forst.   

Abstract

OBJECTIVE: Our objective was to investigate how postprandial processing of intact proinsulin is influenced by different pharmacological strategies in type 2 diabetes mellitus (T2DM). MATERIALS/
METHODS: This exploratory, nonrandomized, cross-sectional study recruited T2DM patients and healthy subjects. Upon recruitment, eligible T2DM patients had been treated for ≥6 months with insulin glargine (GLA) plus metformin (MET), sulfonylureas (SU) plus MET, or dipeptidyl-peptidase-4 inhibitors (DPP-4-I) plus MET. Blood samples were drawn from study participants after an 8 h fast and at regular intervals for up to 5 h after consumption of a standardized meal. Study endpoints included postprandial intact proinsulin and insulin levels and the insulin/proinsulin ratio.
RESULTS: As expected, postprandial secretion of proinsulin was greater in all T2DM treatment groups than in healthy subjects (p < .01 for all comparisons). Postprandial release of proinsulin was significantly greater in T2DM patients treated with SU plus MET than in those treated with GLA plus MET (p = .003). Treatment with DPP-4-I plus MET was associated with reduced proinsulin secretion versus SU plus MET and an increased insulin/proinsulin ratio versus the other T2DM groups.
CONCLUSIONS: Treatment of T2DM with GLA plus MET or DPP-4-I plus MET was associated with a more physiological postprandial secretion pattern of the β cell compared with those treated with SU plus MET.
© 2012 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22768894      PMCID: PMC3440051          DOI: 10.1177/193229681200600318

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  29 in total

1.  The switch from sulfonylurea to preprandial short- acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitus.

Authors:  Andreas Pfützner; Babette Lorra; Michel R Abdollahnia; Peter H Kann; Dominik Mathieu; Christine Pehnert; Christina Oligschleger; Marcel Kaiser; Thomas Forst
Journal:  Diabetes Technol Ther       Date:  2006-06       Impact factor: 6.118

2.  Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn Study.

Authors:  Marjan Alssema; Jacqueline M Dekker; Giel Nijpels; Coen D A Stehouwer; Lex M Bouter; Robert J Heine
Journal:  Diabetes Care       Date:  2005-04       Impact factor: 19.112

3.  Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study.

Authors:  Thomas Forst; Andreas Pfützner; Georg Lübben; Matthias Weber; Nikolaus Marx; Efstrathios Karagiannis; Carsta Koehler; Werner Baurecht; Cloth Hohberg; Markolf Hanefeld
Journal:  Metabolism       Date:  2007-04       Impact factor: 8.694

4.  Intact proinsulin and beta-cell function in lean and obese subjects with and without type 2 diabetes.

Authors:  M E Røder; B Dinesen; S G Hartling; P Houssa; H Vestergaard; F Sodoyez-Goffaux; C Binder
Journal:  Diabetes Care       Date:  1999-04       Impact factor: 19.112

5.  Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year old men using the euglycaemic insulin clamp.

Authors:  B Zethelius; H Lithell; C N Hales; C Berne
Journal:  Diabetologia       Date:  2005-04-01       Impact factor: 10.122

6.  Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS).

Authors:  A Festa; R D'Agostino; L Mykkänen; R P Tracy; D J Zaccaro; C N Hales; S M Haffner
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-03       Impact factor: 8.311

7.  High proinsulin concentration precedes acute myocardial infarction in a nondiabetic population.

Authors:  B Lindahl; B Dinesen; M Eliasson; M Røder; J H Jansson; F Huhtasaari; G Hallmans
Journal:  Metabolism       Date:  1999-09       Impact factor: 8.694

8.  The balance between proinsulin biosynthesis and insulin secretion: where can imbalance lead?

Authors:  Y Uchizono; C Alarcón; B L Wicksteed; B J Marsh; C J Rhodes
Journal:  Diabetes Obes Metab       Date:  2007-11       Impact factor: 6.577

9.  Proinsulin is an independent predictor of the angiographical characteristics of coronary atherosclerosis.

Authors:  En-Zhi Jia; Zhi-Jian Yang; Tie-Bing Zhu; Lian-Sheng Wang; Bo Chen; Ke-Jiang Cao; Jun Huang; Wen-Zhu Ma
Journal:  Cardiology       Date:  2007-10-31       Impact factor: 1.869

10.  Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion.

Authors:  K Kirchhoff; F Machicao; A Haupt; S A Schäfer; O Tschritter; H Staiger; N Stefan; H-U Häring; A Fritsche
Journal:  Diabetologia       Date:  2008-02-09       Impact factor: 10.122

View more
  4 in total

1.  Elevated Intact Proinsulin Levels During an Oral Glucose Challenge Indicate Progressive ß-Cell Dysfunction and May Be Predictive for Development of Type 2 Diabetes.

Authors:  Andreas Pfützner; Iris Hermanns; Sanja Ramljak; Filiz Demircik; Anke H Pfützner; Peter H Kann; Matthias M Weber
Journal:  J Diabetes Sci Technol       Date:  2015-09-29

2.  Anti-diabetic treatment regulates pro-fibrotic TGF-β serum levels in type 2 diabetics.

Authors:  Stefan Pscherer; Thomas Freude; Thomas Forst; Andreas K Nussler; Karl F Braun; Sabrina Ehnert
Journal:  Diabetol Metab Syndr       Date:  2013-08-31       Impact factor: 3.320

3.  Valproic Acid Exposure of Pregnant Rats During Organogenesis Disturbs Pancreas Development in Insulin Synthesis and Secretion of the Offspring.

Authors:  Komariah Komariah; Wasmen Manalu; Bambang Kiranadi; Adi Winarto; Ekowati Handharyani; M Orliando Roeslan
Journal:  Toxicol Res       Date:  2018-04-15

Review 4.  Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.

Authors:  Thomas Forst; Matthias M Weber; Andreas Pfützner
Journal:  Exp Diabetes Res       Date:  2012-04-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.